couter

HRMYHarmony Biosciences Holdings, Inc.

Health CarePharmaceuticals

The Read

9%, on a Q1 earnings miss amid stronger-than-usual market access headwinds despite 17% revenue growth.
Oct 20, 2026 — Fall 2026 Orexin-2 Agonist & Pipeline Update
Chart by TradingView

The schedule

  • Tue20Oct

    Clinical update on HRMY's next-generation orexin-2 receptor agonists and broader pipeline expansion efforts under the President Trump administration's FDA framework.

  • Sun31Jan

    Q3 results will validate whether underlying WAKIX demand can sustain Harmony's +16% YoY revenue growth trajectory.

  • Tue9Feb

    Crucial full-year 2027 net revenue guidance rollout and Q4 profitability check, comparing against the significant EPS miss in the prior year's Q4.

  • Thu6May

    First quarter 2027 results assessing seasonal market access headwinds and early progress on 2027 objectives.

Past

  • Tue4Aug

    Actual outcome: Mixed · $38.75 at outcome

    Harmony reported strong Q2 results, highlighted by a 30% year-over-year increase in WAKIX net revenue to $261.3 million and the reiteration of its full-year revenue guidance of up to $1.04 billion. The company also shared positive initial clinical data for its orexin-2 agonist BP-205. However, with shares already trading near 52-week highs and deeply overbought heading into the print, these positive fundamental developments were largely priced in, resulting in a flat price reaction as investors digested the news.

    Harmony reports Q2 results with shares trading at $37.26, near 52-week highs and deeply overbought (RSI 70.5). Focus is on WAKIX sales growth.

  • Thu7May

    Actual outcome: Mixed · $30.99 at outcome

    Price at outcome date was between bear floor ($28.50) and bull target ($36.00).

  • Tue24Feb

    Actual outcome: Bear · $28.54 at outcome

    Harmony reported a significant Q4 earnings miss of $0.38 per share against an estimated $0.84, representing a sharp year-over-year decline in profitability. While the company reiterated its 2026 revenue guidance of over $1 billion and secured FDA approval for WAKIX in pediatric cataplexy, these developments failed to offset the earnings disappointment, leaving the stock price well below the bear floor.